174 related articles for article (PubMed ID: 26352894)
1. Non-clear cell renal cell carcinoma, part 2: therapy.
Valenca LB; Hirsch MS; Choueiri TK; Harshman LC
Clin Adv Hematol Oncol; 2015 Jun; 13(6):383-91. PubMed ID: 26352894
[TBL] [Abstract][Full Text] [Related]
2. Non-clear cell renal cell carcinoma, part 1: histology.
Valenca LB; Hirsch MS; Choueiri TK; Harshman LC
Clin Adv Hematol Oncol; 2015 May; 13(5):308-13. PubMed ID: 26352775
[TBL] [Abstract][Full Text] [Related]
3. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma.
Procopio G; Verzoni E; de Braud F
Oncology; 2013; 84(1):39-42. PubMed ID: 23076302
[No Abstract] [Full Text] [Related]
5. Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.
Ye D; Eto M; Chung JS; Kimura G; Chang WC; Chang YH; Pang ST; Lee JL; Niu Y; Gurney H; Uemura H
Clin Genitourin Cancer; 2014 Aug; 12(4):225-33. PubMed ID: 24630778
[TBL] [Abstract][Full Text] [Related]
6. New insights into the management of renal cell cancer.
Pécuchet N; Fournier LS; Oudard S
Oncology; 2013; 84(1):22-31. PubMed ID: 23076127
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies: another option for metastatic RCC.
Hutchinson L
Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 24061041
[No Abstract] [Full Text] [Related]
8. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
9. Evolving therapeutic targets in renal cell carcinoma.
Singer EA; Gupta GN; Marchalik D; Srinivasan R
Curr Opin Oncol; 2013 May; 25(3):273-80. PubMed ID: 23455028
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
Kim WY; Kaelin WG
Semin Oncol; 2006 Oct; 33(5):588-95. PubMed ID: 17045088
[TBL] [Abstract][Full Text] [Related]
11. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Gupta S; Fishman M
Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
14. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
16. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
Flaherty KT; Puzanov I
Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy in renal cell carcinoma: advancing paradigms.
Posadas EM; Figlin RA
Oncology (Williston Park); 2012 Mar; 26(3):290-301. PubMed ID: 22545314
[TBL] [Abstract][Full Text] [Related]
18. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
[TBL] [Abstract][Full Text] [Related]
19. Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials.
Ghatalia P; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
Crit Rev Oncol Hematol; 2015 Aug; 95(2):251-63. PubMed ID: 25900071
[TBL] [Abstract][Full Text] [Related]
20. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
